Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Theaflavin is a naturally occurring polyphenolic compound belonging to the biflavonoid class, formed during the oxidation ("fermentation") of catechins in black tea leaves. Its core structure is a benzotropolone derivative, which is responsible for its potent antioxidant activity. Theaflavin displays a range of biological effects including antioxidant, anti-inflammatory, antineoplastic (anticancer), cardiovascular-protective, and antimicrobial actions. Mechanistically, it acts by scavenging free radicals, modulating cellular signaling pathways such as NF-κB and MAPK, and inhibiting pro-inflammatory enzymes like cyclooxygenase and lipoxygenase. It is recognized primarily as a plant metabolite and is not an approved pharmaceutical agent for any indication.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on theaflavin.